The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients.
In a placebo-controlled double-blind randomised group comparison, the tolerability and metabolic effect of emiglitate, a new second-generation alpha-glucosidase inhibitor, was evaluated in 10 Indians with non-insulin-dependent diabetes mellitus being treated with sulphonylureas. Patients on emiglitate showed a decrease in postprandial plasma glucose levels (means 10 +/- 0.94; 10.1 +/- 0.97 mmol/l) compared with the levels in the run-in period (mean 11.4 +/- 1 mmol/l) but the difference was not significant. However, the emiglitate group showed a significantly greater decrease while on the drug compared with the placebo group at the end of the 1st week (P less than 0.01). The Hb A1 levels in those on emiglitate decreased significantly a week after cessation of therapy (mean 7 +/- 0.81%) compared with the run-in levels (mean 9.4 +/- 1.79%; P less than 0.02). The drug was well tolerated and caused no haematological or biochemical abnormalities.